← Leaderboards
Boris C Bastian
University Of California San Francisco
$20,025,092
Attributed
$24,024,755
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,024,755 · 9
By mechanism
R35$6,348,479 · 1
P01$6,100,453 · 3
U01$5,182,743 · 1
R01$4,085,932 · 2
R33$1,218,145 · 1
T32$1,089,003 · 1
Top collaborators
- Scott A Oakes5 shared
- Alan Hunter Shain2 shared
- Iwei Yeh2 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Kevin M Shannon$44,683,939
- Mignon Lee-Cheun Loh$16,050,583
- James E Cleaver$3,201,375
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaMutationTumorMalignant NeoplasmsBaseGenesDna Copy NumberCandidate Disease GeneResponseBraf GeneMelanocytePatternComparative Genomic HybridizationBiologicalGeneticCohortSamplingPathway InteractionsIn VivoInsightBiological MarkersNeoplasm MetastasisLightComplement
Grant awards (44)
Pre-cancer atlas of skin cancer$4,163,730
U01 · FY2025 · CA
Pre-cancer atlas of skin cancer$1,019,013
U01 · FY2024 · CA
Molecular and immunologic evolution of melanomas from pre-neoplastic lesions$920,052
R35 · FY2023 · CA · contact PI
Molecular and immunologic evolution of melanomas from pre-neoplastic lesions$931,980
R35 · FY2022 · CA · contact PI
Molecular and immunologic evolution of melanomas from pre-neoplastic lesions$951,000
R35 · FY2021 · CA · contact PI
Molecular and immunologic evolution of melanomas from pre-neoplastic lesions$951,000
R35 · FY2020 · CA · contact PI
Molecular and immunologic evolution of melanomas from pre-neoplastic lesions$922,472
R35 · FY2019 · CA · contact PI
Molecular and immunologic evolution of melanomas from pre-neoplastic lesions$951,000
R35 · FY2018 · CA · contact PI
Molecular and immunologic evolution of melanomas from pre-neoplastic lesions$720,975
R35 · FY2017 · CA · contact PI
The GNAQ pathway as a therapeutic target in uveal melanoma$306,698
R01 · FY2017 · CA · contact PI
Molecular Pathology of Cancer$244,718
T32 · FY2017 · CA
The GNAQ pathway as a therapeutic target in uveal melanoma$306,698
R01 · FY2016 · CA · contact PI
Molecular Pathology of Cancer$257,347
T32 · FY2016 · CA
The KIT Signaling Pathway as a Therapeutic Target in Melanoma$521,443
P01 · FY2015 · CA · contact PI
The GNAQ pathway as a therapeutic target in uveal melanoma$310,970
R01 · FY2015 · CA · contact PI
Molecular Pathology of Cancer$229,911
T32 · FY2015 · CA
The KIT Signaling Pathway as a Therapeutic Target in Melanoma$572,333
P01 · FY2014 · CA · contact PI
The GNAQ pathway as a therapeutic target in uveal melanoma$301,641
R01 · FY2014 · CA · contact PI
Molecular Pathology of Cancer$242,404
T32 · FY2014 · CA
The KIT Signaling Pathway as a Therapeutic Target in Melanoma$548,613
P01 · FY2013 · CA · contact PI
The GNAQ pathway as a therapeutic target in uveal melanoma$292,312
R01 · FY2013 · CA · contact PI
Molecular Pathology of Cancer$114,623
T32 · FY2013 · CA
The KIT Signaling Pathway as a Therapeutic Target in Melanoma$563,224
P01 · FY2012 · CA · contact PI
Biomarker Discovery for the Classification of Melanoma$319,102
R01 · FY2012 · CA · contact PI
The GNAQ pathway as a therapeutic target in uveal melanoma$310,970
R01 · FY2012 · CA · contact PI
The KIT Signaling Pathway as a Therapeutic Target in Melanoma$553,458
P01 · FY2011 · CA · contact PI
Biomarker Discovery for the Classification of Melanoma$295,929
R01 · FY2011 · CA · contact PI
Biomarker Discovery for the Classification of Melanoma$85,145
R01 · FY2011 · CA · contact PI
The GNAQ pathway as a therapeutic target in uveal melanoma$49,462
R01 · FY2011 · CA · contact PI
Biomarker Discovery for the Classification of Melanoma$457,400
R01 · FY2010 · CA · contact PI
The GNAQ pathway as a therapeutic target in uveal melanoma$320,588
R01 · FY2010 · CA · contact PI
Genetic Expression of Lentigo Malignant Melanoma - UCSF consortium$815,275
P01 · FY2009 · CA · contact PI
Biomarker Discovery for the Classification of Melanoma$379,152
R01 · FY2009 · CA · contact PI
Genetic Expression of Lentigo Malignant Melanoma - UCSF consortium$808,692
P01 · FY2008 · CA · contact PI
Biomarker Discovery for the Classification of Melanoma$349,865
R01 · FY2008 · CA · contact PI
Genetic Expression of Lentigo Malignant Melanoma - UCSF consortium$809,756
P01 · FY2007 · CA · contact PI
Genomic Analysis of Squamous Cell Carcinoma$284,694
P01 · FY2007 · AR · contact PI
Genetic Expression of Lentigo Malignant Melanoma, Proj. 2 - UCSF consortium$317,133
P01 · FY2006 · CA · contact PI
Genetic Expression of Lentigo Malignant Melanoma, Proj. 2 - UCSF consortium$305,832
P01 · FY2005 · CA
Classification of ambiguous melanocytic tumors$287,653
R33 · FY2005 · CA
Classification of ambiguous melanocytic tumors$327,526
R33 · FY2004 · CA
Classification of ambiguous melanocytic tumors$319,630
R33 · FY2003 · CA
Genomic analysis of squamous cell carcinoma$0
P01 · FY2003 · AR
Classification of ambiguous melanocytic tumors$283,336
R33 · FY2002 · CA